Clinical Trial Update: 64Cu-LLP2A for Imaging Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 imaging trial of the radiotracer 64Cu-LLP2A for multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 64Cu-LLP2A (Copper-64 LLP2A)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | EARLY_Phase 1 | Status: TERMINATED